Our mission

Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.

Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.

Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Our vision and strategy

Strategic partnering

Through internal BD capability and access to global innovation network, Overland focuses on cutting-edge technology platforms and programs to deliver maximum value to all stakeholders with strategically tailored partnering structures.

Global R&D innovation

Overland is establishing an in-house discovery engine focused on next-generation regenerative cell therapy by leveraging our current allogeneic platform and China advantage to ultimately serve patients around the world.

Operational efficiency

Therapeutic candidate programs across our portfolio are developed by our dedicated clinical and regulatory teams and other shared functional resources to achieve peak operational and capital efficiency.

Our values

Deep integrity

We are committed to putting patients first and aim at fostering a culture of strong ethics and a high standard for quality.

Entrepreneurial spirit

We are launching a robust research and development engine of differentiated, novel therapeutics – all with the spirit and ambition of a nimble biotech.

Global collaboration

Overland collaborates with innovative partners to jointly develop and strategically commercialize therapeutic programs for entry into Asia and expansion around the globe.

Agility & efficiency

We accelerate the development of and access to promising new medicines for patients by sourcing the brightest talents and centralizing key operations.

Our team

Management


Ed Zhang, MBA

Co-founder and CEO, Overland Pharmaceuticals

Roger Luo, PhD

Chief Development Officer, Head of Clinical & Preclinical Development

Jie Li

Chief Regulatory Officer

Xun Liu, PhD

Chief Technology Officer

Affiliate leadership


Shuyuan Yao, PhD

Allogene Overland Biopharm Chief Executive Officer

Eric Koo, MBA, BPharm

Overland ADCT BioPharma Chief Executive Officer

Strategic advisory


John Maraganore, PhD

Strategic Advisor

Peter Ho, MD, PHD

Strategic Advisor

Functional leadership


Jie Chen, MD, PhD

Head of Biometrics

Warren Li, PhD

Vice President, Head of Translational Medicine

Julia Zhu, MD, PhD

Vice President, Head of Drug Safety & Pharmacovigilance

Helen Yang

Vice President, Head of Clinical Operations & Project Management

Julie Zhang, MBA

Vice President, Head of Regulatory Affairs

Eric Hu, PhD

Vice President, Corporate Development and Strategy

Serena Wang, MBA

Vice President, Head of Finance, IT, & Procurement

Weijie Lan, PhD

Vice President, Head of Cell Therapy Platform Research